Literature DB >> 1478919

A novel core protein as well as polymorphic epithelial mucin carry peanut agglutinin binding sites in human gastric carcinoma cells: sequence analysis and examination of gene expression.

Y Masuzawa1, T Miyauchi, M Hamanoue, S Ando, J Yoshida, S Takao, H Shimazu, M Adachi, T Muramatsu.   

Abstract

The peanut agglutinin (PNA)-binding site is protein-bound Gal beta 1-->3GalNAc, and is a tumor-associated carbohydrate marker expressed in many human carcinomas. PNA-binding glycoproteins isolated from KATO-III human gastric carcinoma cells were deglycosylated by trifluoromethanesulfonic acid, and rabbit antibodies against the core proteins were used to screen a lambda gt11 expression library constructed from these cells. Two different core proteins were identified by this approach. One was polymorphic epithelial mucin (PEM), initially found in breast carcinomas. PEM mRNA was expressed in normal tissues of the stomach, colon, and lung, but not in the small intestine, thyroid, and spleen. High levels of PEM mRNA were detected in some nude mouse-transplanted carcinomas, i.e. colorectal, pancreatic, stomach, and lung carcinomas. The other core protein was a novel one called MGC-24, which has a molecular mass of 24 kDa, is rich in hydroxyl amino acids and cysteine, and lacks repeating motifs. The mature MGC-24 glycoprotein behaved as a high-molecular-mass one upon SDS-polyacrylamide gel electrophoresis even after neuraminidase treatment. Treatment with endo-alpha-N-acetylgalactosaminidase in the absence of neuraminidase significantly changed the staining pattern by anti-MGC-24, confirming that MGC-24 carried PNA-binding sites. MGC-24 mRNA was intensely expressed in normal tissues of the colon, small intestine and thyroid, and in some nude mouse-transplanted colorectal and pancreatic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478919     DOI: 10.1093/oxfordjournals.jbchem.a123948

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  9 in total

1.  Endolyn is a mucin-like type I membrane protein targeted to lysosomes by its cytoplasmic tail.

Authors:  G Ihrke; S R Gray; J P Luzio
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

2.  Selection of a subset of mRNAs from combinatorial 3' untranslated region libraries using neuronal RNA-binding protein Hel-N1.

Authors:  F B Gao; C C Carson; T Levine; J D Keene
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

3.  Protein-bound carbohydrates on cell-surface as targets of recognition: an odyssey in understanding them.

Authors:  T Muramatsu
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

Review 4.  Carbohydrate antigens expressed on stem cells and early embryonic cells.

Authors:  Takashi Muramatsu; Hisako Muramatsu
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

5.  p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.

Authors:  Sabine Heublein; Sabina K Page; Doris Mayr; Nina Ditsch; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-02       Impact factor: 4.553

Review 6.  The stem cell revolution: on the role of CD164 as a human stem cell marker.

Authors:  Suzanne M Watt; Hans-Jörg Bühring; Paul J Simmons; Andrew W C Zannettino
Journal:  NPJ Regen Med       Date:  2021-06-08

7.  Cis-regulatory functions of overlapping HIF-1alpha/E-box/AP-1-like sequences of CD164.

Authors:  Jingqun Tang; Zhaohui Luo; Guangqian Zhou; Chao Song; Fenglei Yu; Juanjuan Xiang; Gang Li
Journal:  BMC Mol Biol       Date:  2011-10-14       Impact factor: 2.946

8.  The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis.

Authors:  A M Havens; Y Jung; Y X Sun; J Wang; R B Shah; H J Bühring; K J Pienta; R S Taichman
Journal:  BMC Cancer       Date:  2006-07-21       Impact factor: 4.430

9.  What makes cancer stem cell markers different?

Authors:  Uwe Karsten; Steffen Goletz
Journal:  Springerplus       Date:  2013-07-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.